High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

  title={High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma},
  author={V{\'i}t Proch{\'a}zka and Edgar Faber and Luděk Raida and Kateřina Langov{\'a} and Karel Indr{\'a}k and Tom{\'a}{\vs} Papaj{\'i}k},
  journal={Leukemia \& Lymphoma},
  pages={1306 - 1310}
Abstract Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma. In this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL). The TK1 level at the time of treatment initiation was… 

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma

Since high TK activity correlated with inferior clinical response as well as inferior progression-free and overall survival after treatment with R-CHOP, the authors suggest that this is most likely to be due to a more malignant tumor phenotype present in a highly proliferative status of the lymphoma.

Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

High TK activity was a strong predictor for short OS and poor response among patients with previously untreated DLBCL treated with R-CHOP.

Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients

TK1 is a tumor marker in HNC patients with the ability to assess response to therapy and high or increasing levels correlated to a poor prognosis, whereas low levels correlation to an overall increased survival.

Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer

Pancreatic ductal adenocarcinomas reveal a significant increase in S-TK activity, which is associated with overall survival, especially in early tumor stages, and may be a useful parameter for monitoring nTx efficacy.

The proliferation marker thymidine kinase 1 in clinical use.

Thymidine kinase 1 (TK1), a cell cycle-dependent and thus a proliferation-related marker, has been extensively studied during the last decades and is an emerging potential proliferating biomarker in oncology that may be used for the prognosis and monitoring of tumor therapy, relapse and survival.

Prognostic Significance of Serum Beta-2 Microglobulin in Patients with Non-Hodgkin Lymphoma

Combining β2-M with IPI may help to improve the prognostic accuracy of NHL and demonstrate an association between serum β1-M and NHL prognosis.

The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma

The detection of serum thymidine kinase 1 might have high clinical value in auxiliary diagnosis, curative effect monitoring, and prognosis judgment of colorectal carcinoma.

Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.

This paper will review TK1 as a tumor biomarker with emphasis on recent studies and technologies plus highlight its potential in drug discovery and as a therapeutic target.

Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT.

Analysis of repeated measurements of TK in serum during treatment of MM patients found a correlation between change in TK measured by DiviTum and LDH during treatment, and combination of positivity of imaging methods which can localize active tumor lesions and increased levels of Tk in serum can have an impact on decision-making and optimization of the therapeutic approach.



High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.

It is shown that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).

High Thymidine Kinase Activity and CD5 Positivity Predict Poor Prognosis Of DLBCL Treated With R-CHOP

It is reported that high thymidine kinase activity (TK) predicts poor prognosis for diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP and CD5 positivity was reported as a poor predictor for DLBCL.

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

Although the number of patients was limited in this study, TK1 in serum might possess an important reference value in the evaluation of treatment and prognosis of non-Hodgkin’s lymphoma following chemotherapy.

Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.

Serological TK1 may be a reliable marker for risk assessment of pre/early cancerous progression of breast and prostate hyperplasia and related diseases.

Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas

  • Zhi-shan LiYinghong Wang S. Skog
  • Medicine
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation
  • 2010
STK1 is a useful marker for prognosis in patients with oesophageal, cardial and lung carcinomas and with NSCLC, and there was a tendency that stage I–IINSCLC patients with an STK1 level above 2 pmol/l showed a higher frequency of recurrence/death than patients below 1‬pmol /l.

Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?

New therapeutic approaches with MoAb, RIT and other biological agents allow the population to be divided into increasing numbers of groups with different outcomes, and accurate prognostic indices are urgently needed to find optimal therapies for particular lymphoma patients.

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy.

Follicular Lymphoma International Prognostic Index.

The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.

Improved survival of follicular lymphoma patients in the United States.

The survival of patients with FL in the United States has improved over the last 25 years, and the survival improvement may be a result of the sequential application of effective therapies and improved supportive care.

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect

It is demonstrated that the FLIPI is able to identify high-risk patients with advanced-stage FL after first-line treatment with rituximab/chemotherapy after a prospective trial of the German Low Grade Lymphoma Study Group.